{"result": "Here is a comprehensive summary of the data:\n\nTRYPHAENA is a clinical trial that investigated the safety and tolerability of dual anti-HER2 antibodies with different regimens. Specifically, it was a randomized phase 2 study that evaluated the safety and tolerability of dual anti-HER2 antibodies combined with NAC (Neoadjuvant chemotherapy). Additionally, TRYPHAENA was also a randomized phase II cardiac safety study. The study reported pCR (Pathological Complete Response) rates, DFS (Disease-Free Survival), and OS (Overall Survival) at the 3-year follow-up.", "input": "\nYou are a helpful assistant responsible for generating a comprehensive summary of the data provided below.\nGiven one or two entities, and a list of descriptions, all related to the same entity or group of entities.\nPlease concatenate all of these into a single, comprehensive description. Make sure to include information collected from all the descriptions.\nIf the provided descriptions are contradictory, please resolve the contradictions and provide a single, coherent summary.\nMake sure it is written in third person, and include the entity names so we the have full context.\n\n#######\n-Data-\nEntities: \"\\\"TRYPHAENA\\\"\"\nDescription List: [\"\", \"\\\"TRYPHAENA is a clinical trial investigating the safety and tolerability of dual anti-HER2 antibodies with different regimens.\\\"\", \"\\\"TRYPHAENA is a randomized phase 2 study that evaluated the safety and tolerability of dual anti-HER2 antibodies combined with NAC.\\\"\", \"\\\"TRYPHAENA is a randomized phase II cardiac safety study.\\\"\", \"\\\"TRYPHAENA is a study that reported pCR rates and DFS and OS at the 3-year follow-up.\\\"\"]\n#######\nOutput:\n", "parameters": {"model": "llama3-8b-8192", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 500, "n": null}}